Estrogen is essential for normal growth and remodeling of bone. Although the mechanism of estrogen action on bone cells has been widely investigated, the full spectrum of signal transduction pathways activated by estrogen is unknown. In this report, we investigate the effects of the gonadal hormone 17␤-estradiol on the regulation of signal transducer and activator 
T HE MOST POTENT natural estrogen, 17␤-estradiol is produced in the ovaries and acts as a hormone on peripheral target tissues. Estrogens, which are found in yeast, fish, reptiles, birds, and all mammals (1), orchestrate intricate regulatory pathways in bone, liver, the cardiovascular system, and reproductive tissues (2) (3) (4) . The well-characterized genomic actions of estrogens are mainly transduced through two nuclear estrogen receptor (ER) isoforms, ER␣ and ER␤ (5) (6) (7) . Additionally, an orphan receptor, ERR-1, with homology to ER, is expressed in bone cells (8, 9) . Multiple transactivation sites on the ER molecule provide the potential for differential ligand-dependent genomic regulation (10) . The discovery of ER-mediated pathways for gene regulation that are not dependent on receptor binding to DNA (11, 12) but require the presence of other transcription factors suggests that there are additional, nongenomic mechanisms of estrogen action (13, 14) .
Stats were first reported in the study of interferon signaling (15) . Subsequently new members of this family have been identified that mediate signals from a variety of cytokines and growth factors (16 -19) . Currently seven different Stat proteins are known to be encoded in distinct genes in mammals, designated as Stat 1, 2, 3, 4, 5a, 5b, and 6 (19, 20) . The Stat signaling pathways involve ligand-induced receptor dimerization, tyrosine phosphorylation, homo-or heterodimerization of phosphorylated Stat proteins, translocation of Stat dimers to the nucleus, and binding to specific DNA sequences to regulate transcription of specific genes (15) .
Stat proteins participate in IL-6-mediated regulation of osteoblast differentiation (21) and fibroblast growth factormediated inhibition of chondrocyte proliferation and bone development (22) . In this study, we demonstrate that estrogen activates Stat1 protein in human fetal osteoblasts (hFOBs) and malondialdehyde (MDA) MB-231 breast cancer cells, both of which are devoid of ER, providing evidence for a previously unrecognized nongenomic estrogen action.
PP3 (4-amino-7-phenylpyrazol [3,4-d] pyrimidine) were purchased from Calbiochem (San Diego, CA). Luciferase constructs containing ␥-activated sequence (GAS) elements were provided by Dr. Aseem Kumar (Laurentian University, Sudbury, Ontario, Canada). Luciferase constructs containing interferon-stimulated response element (ISRE) were purchased from Stratagene (La Jolla, CA). The dominantnegative Stat1 cDNA encoding the protein that lacks major phosphorylation site (due to mutation from tyrosine to phenylalanine at position 701) was kindly provided by Dr. Jaharul Haque (Cleveland Clinic Foundation, Cleveland, OH).
Construction of GAS mutant promoter-driven luciferase reporter plasmid
The 7 ϫ GAS-mutant promoter-driven luciferase (GASM-luciferase) vector was generated by PCR and ligation as described (23) . PGL3 Basic vector (Promega, Madison, WI) was linearized by digesting at SmaI site, and then the entire plasmid was amplified using forward primer that has seven repeats of mutant GAS elements at 5Ј-end (ATA GCG TAA ATA GCG TAA ATA GCG TAA ATA GCG TAA ATA GCG TAA ATA GCG TAA GGG CTC GAC ATC TGC GAT CTA AGT) and the reverse primer sequence (GGG CTA GCA CGC GTA AGA GCT CGG). Underlined sequences represent mutant GAS elements. Nonunderlined sequences represent vector. The amplified fragments were self-ligated and transformed, and large-scale plasmid purification was carried out as described (23) . The cloning of GAS mutant sequences in the vector was confirmed by DNA sequencing at the Molecular Core Facility, Mayo Clinic.
Cell culture and estrogen treatment
The hFOB cell line containing the temperature sensitive T antigen expression vector with neomycin resistance gene (24) was maintained at 34 C in phenol red-free DMEM/F12 containing 10% charcoal-stripped fetal bovine serum supplemented with geneticin (300 g/ml) as described (24, 25) . MDA-MB231 (ER-negative) breast cancer cells were maintained at 37 C in phenol red-free DMEM/F12 medium containing 10% charcoal-stripped fetal bovine serum as described (26) . The cells were plated 24 h before estrogen treatment. Cells were grown in T-75 flasks at 1 ϫ 
Cell lysis and preparation of cytoplasmic and nuclear extracts
Estrogen-treated cell pellets were lysed by suspending in Nonidet P-40 lysis buffer containing 0.5% Nonidet P-40; 90 mm KCl; 1 mm magnesium acetate; 2 mm 2-mercaptoethanol; 10 g/ml leupeptin; 1ϫ phosphatase inhibitor cocktail 2 (a mixture of sodium orthovanadate, sodium molybdate, and sodium tartrate) (Sigma); and 10 mm HEPES (pH 7.6). After centrifugation at 10,000 ϫ g for 10 min, the resultant supernatant containing cytoplasmic extract was used for immunoprecipitation, and the pellets containing nuclei were saved for preparing nuclear extract (27) .
Immunoprecipitation analyses
Cytoplasmic cell extracts (60 g protein) were used for immunoprecipitation with 1 g of the anti-phosphoStat or anti-Stat1 antibody (Santa Cruz Biotechnology, San Diego, CA). Bound proteins were purified using protein A Sepharose. Immunoprecipitated proteins were separated by SDS-PAGE and analyzed by Western blotting. For coimmunoprecipitation studies, cell extracts containing equal amounts of protein were immunoprecipitated with anti-Src (Cell Signaling Technology, Beverly, MA), anti-Stat1 antibody, or nonimmune IgG (Dako Cytomation, Carpinteria, CA). The immunoprecipitates were incubated with protein A Sepharose for 1 h at 4 C and then washed and separated on SDS-PAGE gel and analyzed by Western blotting using anti-Src and anti-Stat1 antibodies.
EMSAs
Nuclear extracts (15 g protein) prepared from hFOB cells were used in EMSAs as described in the manufacturer's protocol (GENEKA, Montréal, Canada). Where indicated, the reactions were incubated with equal concentrations of cold and hot mutant and wild-type double-stranded DNA sis-inducible element (SIE) oligonucleotides provided in the kit as described (GENEKA). The following SIE oligonucleotides were used in this experiment (sequence of the sense strand is shown): wild-type SIE oligonucleotide, 5Ј-GTC GAC ATT TCC CGT AAA TCG TCG A-3Ј; and mutant SIE oligonucleotide, GTC GAC ATA TAG CGT AAA TCG TCG A-3Ј. The binding reactions were subjected to electrophoresis on a 5% polyacrylamide gel in 0.5ϫ Tris-borate EDTA running buffer. Gels were analyzed on a PhosphorImager analyzer (Molecular Dynamics Inc., Sunnyvale, CA).
Luciferase assay
Luciferase constructs containing GAS elements (28) and luciferase constructs containing ISRE elements (Stratagene) were used in this study. Cells plated in 6-well plates were transfected at 60% confluence with pGAS-luciferase using the transfection agent lipofectamine as described in the manufacturer's protocol (Invitrogen, Carlsbad, CA). The plasmids pISRE-luciferase, luciferase driven by pGASM-luciferase and dominant-mutant Stat1 cDNA (DN-Stat1) were used in various transfection experiments as indicated. All transfections performed had an internal transfection control plasmid containing Renilla luciferase (pRL-CMV-luciferase) (Promega), which also allowed normalization of luciferase units. Twenty-four hours post transfection, the cells were treated with 20 nm E 2 , 100 nm ER antagonist ICI 182,780, or 25 m Src-kinase family inhibitor pyrazolopyrimidine compound (PP2). The cells were harvested after 48 h of treatment using 300 l of passive lysis buffer provided in a luciferase assay kit (Promega). Luciferase assays were performed using the dual luciferase reporter assay system according to the manufacturer's protocol (Promega) and read on a TD-20E luminometer (Turner, Sunnyvale, CA).
Statistical analysis
All values are expressed as mean Ϯ se. In each experiment, three to eight replicates of each treatment were measured. The data are representative of three independent experiments. Fisher's protected least significant difference with a one-way ANOVA was used to compare the groups. P Ͻ 0.05 was considered statistically significant. Due to the small sample size in some of the groups, we supplemented the ANOVA with nonparametric Kruskal-Wallis tests.
Results

Effect of estrogen on Stat1 protein phosphorylation
E 2 treatment resulted in an increased tyrosine phosphorylation of Stat1 within 15 min of treatment as shown by Western blot hybridization using an anti-phosphoStat1 antibody [p-Stat1 (Tyr 701)] directed against the tyrosine phosphorylated residue of Stat1 (Fig. 1A) . The increase in phosphorylation appears to be transient and decreases with time. In contrast, there was no significant change in the total amount of Stat1 protein with E 2 treatment as detected by anti-Stat1␣ p91 antibody (Fig. 1B) .
Estrogen treatment leads to activation and formation of Stat1-DNA complex
Nuclear extracts prepared from hFOB cells treated with E 2 were analyzed by EMSA (Fig. 2) . Stat1 binding to radiolabeled wild-type oligonucleotide probe increased in hFOB cells in the presence of E 2 (lane 7), compared with the vehicle control (lane 3). The specificity of Stat1 binding was confirmed by decreased binding in the presence of nonradio- 
Estrogen treatment increases Stat1-dependent transcriptional activity in osteoblast cells
To determine whether estrogen treatment induces Stat1-stimulated transcription and whether Stat1-dependent promoter activities are involved in estrogen-mediated activation, the effects of E 2 was tested on both the ISRE-and GAS-driven luciferase activities by transient transfection assays in hFOB cells. Relative to the activity in untreated cells, estrogen stimulated the GAS-luciferase reporter gene activity approximately 8-fold (vehicle 0.8 Ϯ 0.3; estrogen 7 Ϯ 0.2) (Fig. 3A) . As expected, interferon-␥ treatment led to even greater stimulation of the reporter activity (Ͼ100-fold) (vehicle 0.8 Ϯ 0.3; interferon 212 Ϯ 2.5) (Fig. 3A) . A timedependent increase in GAS-luciferase reporter gene activity occurred after E 2 treatment (vehicle 0.9 Ϯ 0.2; estrogen treatment 8 h, 2. Ϯ 0.1; 12 h, 2.5 Ϯ 0.8; 24 h, 3.7 Ϯ 0.3; 48 h, 7.6 Ϯ 0.1) (Fig. 3B ). GAS promoter with mutations in the sequences was not activated in response to estrogen treatment, and no increase in luciferase activity was observed in cells transiently transfected with luciferase constructs driven by GAS mutant promoter (vehicle 6.6 Ϯ 0.3; estrogen 8 Ϯ 0.6) (Fig. 3C) . Estrogen treatment led to a small change on ISREdriven luciferase activity (vehicle 1.8 Ϯ 0.1, estrogen 2.2 Ϯ 0.1) (Fig. 3D) , whereas interferon-␤ treatment stimulated ISRE-luciferase promoter functions (vehicle 6.6 Ϯ 0.3, estrogen 217 Ϯ 10.5) (Fig. 3D) .
Activation of Stat1-dependent GAS promoter activity by estrogen is supported by experiments in cells cotransfected with dominant-negative Stat1 mutant cDNA, in which the E 2 -mediated activation of GAS luciferase activity was decreased (Fig. 4) . Relative to the activity in untreated cells, estrogen stimulated GAS-luciferase reporter gene activity in the absence or presence of DN-Stat1 by 6.3-and 3.2-fold, respectively (vehicle 1.5 Ϯ 0.1; estrogen 8.6 Ϯ 0.6; estrogenϩDN-Stat1 4.4 Ϯ 0.4; DN-Stat1 2. 8 Ϯ 0.2) (Fig. 4) .
However, ER-dependent activation of estrogen response element (ERE) and ERE-controlled expression of luciferase activity were not blocked (Fig. 4) . Relative to the activity in untreated cells, estrogen stimulated ERE-luciferase reporter gene activity in the absence or presence of DN-Stat1 by 4.6-and 3.9-fold, respectively (vehicle 2.8 Ϯ 0.1; estrogen 12.4 Ϯ 0.6; estrogenϩDN-Stat1 11 Ϯ 0.5, DN-Stat1 2.5 Ϯ 0.2) (Fig. 4) .
Estrogen-mediated activation of Stat1 is ER independent
ER antagonist ICI 182,780 blocked estrogen-stimulated ERE-luciferase activity in hFOB cells (data not shown). In contrast, ICI 182,780 did not block E 2 -stimulated GAS-driven luciferase activity (vehicle 1.2 Ϯ 0.1; estrogen 9 Ϯ 0.1; estrogenϩICI 182,780 8.6 Ϯ 0.7) (Fig. 5) .
Estrogen treatment induces Stat1 activation in ER-negative breast cancer cells
To determine target cell specificity, Stat1 phosphorylation was investigated in E 2 -treated breast cancer cells. Estrogen treatment resulted in an increased tyrosine phosphorylation of Stat1 within 15 min in ER-negative (MDA-MB231) breast cancer cells as shown by Western blot hybridization with p-Stat1(Tyr 701) antibody (Fig. 6A) . As was the case in bone cells, there was no significant change in the total amount of Stat1 protein with estrogen treatment in the breast cancer cells (Fig. 6B) .
The effects of E 2 on GAS-driven luciferase activities were examined by transient transfection assays in MDA-MB231 breast cancer cells to determine whether E 2 treatment induces Stat1-stimulated transcription and whether Stat1-dependent promoter activity is involved. Relative to the activity in untreated cells, E 2 at 10, 20, and 100 nm stimulated the GAS-luciferase reporter gene activity by 1.2-, 4.9-, and 9-fold, respectively (vehicle 2.8 Ϯ 0.2, estrogen 10 nm, 4.9 Ϯ 0.5; 20 nm, 15.7 Ϯ 0.4; 100 nm, 27.8 Ϯ 0.4) (Fig. 7) .
Estrogen-mediated activation of Stat1 requires Src kinase activity
Estrogen-stimulated GAS-luciferase expression was blocked in the presence of Src kinase inhibitor, PP2 (vehicle 2.1 Ϯ 0.3; estrogen 14 Ϯ 0; estrogenϩPP2 4 Ϯ 0.4) (Fig. 8), whereas the epidermal growth factor receptor kinase inhibitor PP3, which serves as a negative control for PP2 and does not inhibit Src kinase activity, had no effect (estrogenϩPP3 13.4 Ϯ 0.6) (Fig. 8) . Neither PP2 nor PP3 showed any significant independent effect on GAS luciferase activity (PP2 4.8 Ϯ 1; PP3 4.5 Ϯ 1). In cells that transiently express dominant-negative Src protein, estrogen-dependent GASluciferase activity was inhibited (data not shown).
Src is associated with Stat1 in estrogen-treated osteoblasts
Coimmunoprecipitation studies in estrogen-treated hFOB cells analyzed by Western blot hybridization demonstrated c-Src protein coimmunoprecipitated with Stat1 (Fig. 9A) . Both Stat1 and activated Stat1 proteins coimmunoprecipitated with c-Src as shown by anti-Stat1 and pStat1 antibodies (Fig. 9B) . No signals were observed with nonimmune IgG controls (Fig. 9C) .
The luciferase activity results for all statistical analysis based on nonparametric Kruskal-Wallis tests were similar to those based on ANOVA (data not shown).
Discussion
Estrogen treatment leads to tyrosine phosphorylation and rapid (within 15 min) activation of Stat1 protein in ERnegative human osteoblast cells. This immediate response is followed by an increase in Stat1-specific DNA binding and transcription, which does not require classical ERs. In addition, the activation of Stat1 protein and the stimulation of Stat1-dependent transcription by estrogen in ER-negative breast cancer cells suggest that this could be a common signaling mechanism in estrogen target cells.
Many of the post-2 h actions of estrogen involve the genomic mechanism, which involves the binding of estrogen to ER, translocation of ligand bound receptors to the nucleus, followed by homo-or heterodimerization of ER and binding of ER dimers to estrogen-responsive elements on the DNA. The rapid (15 min) effects of estrogen described in this study occur too quickly for genomic-mediated mechanisms (13, 14, 29) . Several other reports on the nongenomic actions of estrogens have been shown to occur much more rapidly, and some report the involvement of MAPK, Src, or phosphatidylinositol 3-kinase pathways (14, 29 -31) .
The estrogen-mediated activation of Stat1 described here is not inhibited by cycloheximide (Kennedy, A., A. Maran, and R. T. Turner, unpublished data). Unlike previously described nongenomic effects in bone cells, Stat1 activation by estrogen does not require classical ER, as shown by the failure of the ER antagonist ICI 182,780 to block the Stat1-dependent transcription. This finding may be analogous to the nongenomic activation of ERK MAPKs by estrogen in the explants of cerebral cortex (32) . Estrogen increases type 1 collagen levels and alkaline phosphatase activity in hFOB cells (Maran, A., and R. T. Turner, unpublished data), indicating that activation of non-ER-mediated pathways by the hormone results in metabolic changes in bone cells. Stat1 protein-dependent transcriptions involve the binding of Stat1 to two specific promoter elements, namely ISRE and GAS in cytokines and growth factor-treated cells (15, 33, 34) . The Stat family members show specificity in DNA binding: Stat1 homodimer binds to GAS, whereas the Stat1/Stat2 heterodimer interacts with ISRE. E 2 activation of Stat1 protein results in increased transcription of GAS element-containing genes. Estrogen's preference for the GAS over the ISRE suggests that estrogen elicits responses similar to interferon-␥ or ligands like IL-6 and platelet-derived growth factor (33, 35, 36) . Stat1 binding GAS elements are present in the regulatory regions of genes expressed by osteoblasts, such as type 1 collagen, osteocalcin, and osteonectin. Further work is necessary to determine the effects of estrogen-mediated activation of Stat1 activity on osteoblast metabolism.
The involvement of Stat1 protein in estrogen-mediated actions of osteoblasts differs from a recent report showing estrogen-mediated, nongenomic activation in endothelial cells involving other Stat family members (Stat 3 and 5) in an ER-dependent manner (31) . One report (14) has shown that an alternative form of ER could mediate some of the nongenomic actions of estrogens. Preliminary findings suggest that a subset of the classical ER is associated with the cell membrane (14, 32) and such putative membrane ERs have been found to be insensitive to antiestrogen ICI 182,780 treatment (32) . The present findings do not address whether such membrane ERs are present in hFOB cells and could play a role in estrogen-mediated activation of Stat1 signaling.
Several known mechanisms lead to tyrosine phosphorylation and activation of Stat proteins in cells, including: 1) cytokine receptors that activate Janus kinases, which in turn phosphorylate Stat proteins (e.g. interferon and IL-6 receptors); 2) phosphorylation by growth factor receptors that have intrinsic tyrosine kinase activities (e.g. platelet-derived growth factor, epithelial growth factor receptors); or 3) direct phosphorylation by nonreceptor tyrosine kinases (e.g. Src, Fes, Abl). Stat1-dependent GAS promoter activity was inhibited in the presence of a chemical inhibitor for c-Src kinase, and both Stat1 and activated Stat1 are associated with c-Src kinase protein. The association of other Stat family members with Src protein has been demonstrated in cancer cells and cytokine-dependent signaling (37) (38) (39) (40) . This suggests that estrogen-mediated activation of Stat1 protein in hFOB cells is dependent on the Src kinase pathway. Further work is necessary to determine whether Src kinase plays a role in Stat1 phosphorylation in estrogen-treated bone cells. These results are consistent with the rapid activation of Src kinase shown previously in osteoblasts and osteocytes after estrogen exposure (14) . Thus, Stat1 association with activated Src kinase in estrogen-treated cells supports a potentially vital role for Src kinase pathway in Stat1 activation by estrogen in target cells.
In conclusion, ER-independent activation of Stat1 in E 2 -treated bone and breast cancer cells presents a novel nongenomic, non-ER-mediated mechanism for estrogen action and reinforces the concept that estrogen involves multiple signaling pathways in target cells. 
